[A preparation of cytotoxic T-lymphocytes (CTL) specifically reactive to Epstein-Barr virus (EBV) latent membrane protein-2A (LMP2A) with potential antineoplastic activity. T-lymphocytes are exposed ex vivo to dendritic cells (DCs) transfected with a replication-deficient adenovirus encoding EBV LMP2A. These LMP2A-specific CTLs are subsequently exposed to EBV infected cells transfected with adenovirus encoding LMP2A, thereby further stimulating CTLs. Administered into patients with EBV-positive tumors, LMP2A-specific CTLs target LMPA-positive cells, resulting in cell lysis and inhibition of cancer cell proliferation. EBV LMP2A is expressed in various EBV-positive malignancies, including nasopharyngeal carcinoma, EBV-positive Hodgkin's and non-Hodgkin's lymphomas. ( NCI )]
UMLS (NCI) C1328049LMP2A-Specific CTL
LMP2A-Specific Cytotoxic T-Lymphocytes
- Cell
- Pharmacologic Substance